Furthermore, treating hypertension with ACE inhibitors or angiotensin receptor blockers (ARBs) can increase ACE2 levels, making COVID-19 patients more vulnerable to SARS-CoV-2 infection and decreasing their prognosis. This evidence concerns the gene ACE and hypertensive disorder.